Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/3/2025

Management of Hypertension in Patients with Congestive Heart Failure

First-Line Medications for Hypertension in CHF

  • The American Heart Association recommends ACE inhibitors, ARBs, beta-blockers, and aldosterone receptor antagonists as first-line antihypertensive medications for patients with heart failure, as they have been proven to improve outcomes including mortality and hospitalization reduction 1, 2
  • The American College of Cardiology recommends ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) as first-line therapy for hypertension in CHF patients with Heart Failure with Reduced Ejection Fraction (HFrEF) 3, 1, 4
  • Beta-blockers (specifically carvedilol, metoprolol succinate, bisoprolol, or nebivolol) should be included in the treatment regimen for patients with HFrEF, according to the American Heart Association 1, 2
  • The European Society of Cardiology recommends aldosterone receptor antagonists (spironolactone or eplerenone) for patients with NYHA class II-IV symptoms and ejection fraction <40% 1, 4
  • Diuretics (thiazide or loop diuretics) should be used for volume control and BP management in patients with CHF, as recommended by the American College of Cardiology 1, 2
  • The European Heart Journal recommends SGLT2 inhibitors to improve outcomes in patients with HFrEF/HFmrEF 3

Target Blood Pressure Goals

  • The European Heart Journal recommends a target systolic BP of 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg for most patients with CHF 3
  • For older patients (≥65 years) with CHF, the European Heart Journal recommends a target systolic BP range of 130-139 mmHg 3
  • Individualized BP targets are recommended for those with lower eGFR or renal transplantation, according to the European Heart Journal 3

Special Considerations

  • The American Heart Association recommends hydralazine plus isosorbide dinitrate for African American patients with NYHA class III or IV HF, in addition to the standard regimen of diuretic, ACE inhibitor/ARB, and beta-blocker 1, 4
  • The European Heart Journal recommends initial antihypertensive treatment with a diuretic or a CCB, either in combination or with a RAS blocker, for black patients 3
  • For resistant hypertension in CHF, the European Heart Journal recommends adding low-dose spironolactone to existing treatment 3
  • If intolerant to spironolactone, the European Heart Journal suggests considering eplerenone, amiloride, higher dose thiazide/thiazide-like diuretic, or loop diuretic 3
  • Carvedilol may be more effective than other beta-blockers for resistant hypertension due to its combined α1-β1-β2-blocking properties, according to the American Heart Association 8

Medications to Avoid in CHF

  • The American College of Cardiology recommends avoiding non-dihydropyridine calcium channel blockers (verapamil, diltiazem) in patients with HFrEF due to negative inotropic effects 1, 2, 9
  • Clonidine and moxonidine should be avoided in patients with CHF, according to the American Heart Association 1, 10
  • Alpha-adrenergic blockers like doxazosin should be used only if other medications fail to achieve BP control, as recommended by the American College of Cardiology 1, 2
  • Hydralazine without a nitrate should be avoided in patients with CHF, according to the American Heart Association 1, 6

Practical Approach to Medication Selection

  • The American Heart Association recommends starting with an ACE inhibitor (e.g., lisinopril) or ARB if ACE inhibitor is not tolerated, and adding a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) 1, 4
  • Diuretics should be included for volume control (thiazide for mild symptoms, loop diuretics for severe HF), according to the American College of Cardiology 1, 2
  • An aldosterone receptor antagonist (spironolactone or eplerenone) should be added if ejection fraction <40%, as recommended by the American Heart Association 1, 4
  • The European Heart Journal recommends considering SGLT2 inhibitors for both HFrEF and HFpEF 3

Common Pitfalls to Avoid

  • The American Heart Association recommends monitoring renal function and potassium when using ACE inhibitors or aldosterone antagonists, especially in combination, to avoid underdosing ACE inhibitors 1, 4
  • Non-dihydropyridine CCBs should be avoided in HFrEF patients, according to the American College of Cardiology 1, 9
  • Excessive BP lowering in elderly patients should be avoided, with a target systolic BP <130 mmHg in patients >65 years, as recommended by the European Heart Journal 3
  • The American College of Cardiology recommends adjusting medication regimen based on ejection fraction status (HFrEF vs. HFpEF) 3, 2

REFERENCES

← Return to Home